Skip to main content

Table 10 Predictive risk of CCA recurrence in early stage patients using either the combination of soluble CSC markers, CD44, CD44v6, CD44v8-10 and EpCAM or the combination of soluble CSC markers with CA19-9

From: Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma

Comparative predictionORpORp
Crude(95% CI)Adjusted(95% CI)
Post-operative recurrence
 Levels of all markers ≥ cut-offa
  Nob (46)10.00410.006
  Yes (14)7.08(1.867–26.870)7.39(1.760–31.071)
 CA19-9 ≥ 37 U/mL + Levels of all markers ≥ cut-off
  No + No and Yes + No and No + Yes (36)10.00510.011
  Yes + Yes (9)12.25(2.114–70.986)15.28(1.879–124.320)
  1. OR odds ratio, OR adjusted odds ratio adjusted for age and sex statistical analysis, 95% CI 95% confidence interval
  2. aLevels of all markers: levels of CD44, CD44v6, CD44v8-10 and EpCAM
  3. bNo: patients with at least one of marker lower than a designated cut-off